AI Article Synopsis
- Mammalian cells are the primary hosts for producing therapeutic monoclonal antibodies (mAbs) because they produce properly assembled antibodies with human-compatible glycosylation profiles.
- GlycoFi, a subsidiary of Merck & Co., has modified the Pichia yeast glycosylation pathway, allowing it to create glycoproteins with a human-like glycan profile, potentially offering a more efficient alternative to mammalian systems.
- The chapter outlines a detailed protocol for using glycoengineered Pichia for mAb production, including techniques for expression vector construction, yeast transformation, high-throughput strain selection, fermentation, and purification of antibodies.
Article Abstract
Currently, mammalian cells are the most commonly used hosts for the production of therapeutic monoclonal antibodies (mAbs). These hosts not only secrete mAbs with properly assembled two heavy and two light chains but also deliver mAbs with a glycosylation profile that is compatible with administration into humans. GlycoFi, a wholly owned subsidiary of Merck & Co., Inc., humanized the Pichia glycosylation pathway which allows it to express glycoproteins with a human-like glycan profile. This offers an alternative mAb production platform similar to mammalian hosts and in some cases it even provides more homogenous product and better efficacy, such as enhanced effector function. This chapter describes a protocol for using glycoengineered Pichia to produce full-length mAbs. It covers a broad spectrum of mAb expression technologies in yeast including expression vector construction, yeast transformation, high-throughput strain selection to fermentation, and antibody purification.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/978-1-62703-327-5_3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Optogenetic Clustering and Stimulation of the T Cell Receptor in Nongenetically Modified Human T Cells.
Methods Mol Biol
December 2024
INM-Leibniz Institute for New Materials, Saarbrücken, Germany.
Methods for the precise temporal control of cell surface receptor activation are indispensable for the investigation of signaling processes in mammalian cells. Optogenetics enables such precise control, but its application in primary cells is limited by the imperative for genetic manipulation of target cells. We here describe a method that overcomes this obstacle and enables the precise activation of the T cell receptor in nongenetically engineered human T cells by light.
View Article and Find Full Text PDFLinsitinib inhibits proliferation and induces apoptosis of both IGF-1R and TSH-R expressing cells.
Front Immunol
December 2024
Molecular Thyroid Research Laboratory, Department of Medicine I, Johannes Gutenberg-University (JGU) Medical Center, Mainz, Germany.
Background: The insulin-like growth factor 1 receptor (IGF-1R) and the thyrotropin receptor (TSH-R) are expressed on orbital cells and thyrocytes. These receptors are targeted in autoimmune-induced thyroid eye disease (TED). Effective therapeutic treatment of TED inhibits activation of the IGF-1R/TSH-R complex.
View Article and Find Full Text PDF[Targets and mechanisms of neutralizing monoclonal antibodies against Dengue virus].
Sheng Wu Gong Cheng Xue Bao
December 2024
CAS Key Laboratory of Pathogenic Microbiology & Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China.
Dengue fever is a mosquito-borne disease prevalent in tropical and subtropical regions, with its prevalence expanding due to increased global travel. The dengue virus, the causative agent of dengue fever, often co-circulates in the form of four distinct serotypes. Cross-reactive antibodies generated during a primary infection pose a significant risk during secondary infections with different serotypes, and fully protective vaccines and antiviral drugs are yet to be developed.
View Article and Find Full Text PDFTLR4 Targeting: A Promising Therapeutic Approach Across Multiple Human Diseases.
Curr Protein Pept Sci
December 2024
Department of Pharmacy, Galgotias University, Greater Noida, Uttar Pradesh 201310, India.
TLR4 stands at the forefront of innate immune responses, recognizing various pathogen- associated molecular patterns and endogenous ligands, thus serving as a pivotal mediator in the immune system's defense against infections and tissue damage. Beyond its canonical role in infection, emerging evidence highlights TLR4's involvement in numerous non-infectious human diseases, ranging from metabolic disorders to neurodegenerative conditions and cancer. Targeting TLR4 signaling pathways presents a promising therapeutic approach with broad applicability across these diverse pathological states.
View Article and Find Full Text PDFComparative Effectiveness of Antivirals and Monoclonal Antibodies for Treating COVID-19 Patients Infected With Omicron Variant: A Systematic Review and Network Meta-Analysis.
Influenza Other Respir Viruses
December 2024
Laboratory of Data Discovery for Health Limited (D24H), Hong Kong Science Park, new Territories, Hong Kong SAR, China.
Antiviral drugs likely remain effective against the SARS-CoV-2 Omicron variant, while monoclonal antibody (mAb) therapies have experienced drops in neutralizing ability. This systematic review and network meta-analysis aims to estimate the comparative effectiveness of antivirals and mAb therapies for treating COVID-19 patients infected with Omicron, capturing primarily acute outcomes. We searched multiple databases from July 4 to July 19, 2022, with updates through November 4, 2022.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!